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Abstract
Background: Maternal folic acid (FA) supplementation before and in early pregnancy prevents neural tube defects
(NTD), but it is uncertain whether continuing FA after the first trimester has benefits on offspring health. We aimed
to evaluate the effect of FA supplementation throughout pregnancy on cognitive performance and brain function
in the child.
Methods: Follow-up investigation of 11-year-old children, residing in Northern Ireland, whose mothers had
participated in a randomised trial of Folic Acid Supplementation in the Second and Third Trimesters (FASSTT) in
pregnancy and received 400 μg/day FA or placebo from the 14th gestational week. Cognitive performance (Full
Scale Intelligence Quotient, Verbal Comprehension, Working Memory, Perceptual Reasoning, and Processing Speed)
was assessed using the Wechsler Intelligence Scale for Children. Neuronal function was assessed using
magnetoencephalographic (MEG) brain imaging.
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Results: Of 119 mother-child pairs in the FASSTT trial, 68 children were assessed for neurocognitive performance at
11-year follow-up (Dec 2017 to Nov 2018). Children of mothers randomised to FA compared with placebo scored
significantly higher in two Processing Speed tests, i.e. symbol search (mean difference 2.9 points, 95% CI 0.3 to 5.5,
p = 0.03) and cancellation (11.3 points, 2.5 to 20.1, p = 0.04), whereas the positive effect on Verbal Comprehension
was significant in girls only (6.5 points, 1.2 to 11.8, p = 0.03). MEG assessment of neuronal responses to a language
task showed increased power at the Beta (13–30 Hz, p = 0.01) and High Gamma (49–70 Hz, p = 0.04) bands in
children from FA-supplemented mothers, suggesting more efficient semantic processing of language.
Conclusions: Continued FA supplementation in pregnancy beyond the early period currently recommended to
prevent NTD can benefit neurocognitive development of the child. MEG provides a non-invasive tool in paediatric
research to objectively assess functional brain activity in response to nutrition and other interventions.
Trial registration: ISRCTN ISRCTN19917787. Registered on 15 May 2013.
Keywords: Prenatal folic acid, Pregnancy, Randomised controlled trial, Child cognition, Neuronal function, Wechsler
Intelligence Scale for Children, Magnetoencephalographic brain imaging
Background
Folate is essential in early life, with conclusive evi-
dence that periconceptional supplementation with
folic acid (FA; the synthetic vitamin form) is effective
in preventing the first occurrence [1] and recurrence
[2] of neural tube defects (NTD). This evidence has
led to recommendations that are in place worldwide
for women to take FA from before conceiving until
the end of the first trimester. What is less clear is
whether continued FA supplementation after the first
trimester of pregnancy can confer longer term health
benefits to the child. Emerging evidence however
shows that the period of rapid growth and develop-
ment of the foetal brain occurring in later pregnancy
is particularly sensitive to maternal folate concentra-
tions [3]. Also, myelination of the brain, which is
most intensive from mid-gestation to the second year
of life [4] and essential for cognitive development as
it protects nerve axons and facilitates communication
between neurons, may be particularly vulnerable to
deficiency of folate [5]. Several studies have investi-
gated the association of maternal folate in pregnancy
with neurocognitive development in the child [6].
Over 40 years ago, Gross et al. showed that children
born to mothers diagnosed with folate-related meg-
aloblastic anaemia in the third trimester of pregnancy
had abnormal neurodevelopment and lower intellec-
tual abilities, compared to infants born to mothers
with optimal folate status [7]. Decades later, a longi-
tudinal transgenerational study found that optimal
maternal folate status during later pregnancy was as-
sociated with better cognitive performance in the
child at 9–10 years [8]. Another study of note used
magnetic resonance imaging (MRI) of the child’s
brain along with cognitive tests and found that
maternal folate deficiency in later pregnancy was
associated with, not only lower language and visuo-
spatial abilities, but also reduced brain volumes in
children aged 6–8 years [9].
A major limitation in the aforementioned studies is
that they are observational and thus, by design, can-
not demonstrate that maternal folate nutrition is
causatively linked with cognitive outcomes in the off-
spring [6]. More robust evidence was however pro-
vided in our recent follow-up study of children whose
mothers had participated in a randomised trial of
Folic Acid Supplementation in the Second and Third
Trimesters (FASSTT) [10] and showed improved psy-
chometrically measured cognition at 3 years and word
reasoning (verbal IQ) at 7 years in the children of
mothers randomised to receive FA in pregnancy [11].
The latter study, and almost all previous research in
this area, involved psychological tests to assess neuro-
development in children, whereas direct measure-
ments of neuronal activity in the brain have rarely
been employed. Magnetoencephalography (MEG) is a
non-invasive neuroimaging modality that measures
the magnetic fields associated with neuronal currents
generated by the brain and may thus provide a robust
platform for investigating neurodevelopment in
children [12]. Therefore, in the present FASSTT
Offspring trial, we aimed to evaluate the effect of FA
supplementation during pregnancy on cognitive per-
formance and MEG-assessed brain functioning in the
child at 11 years. Our hypothesis was that the higher
verbal IQ previously found in the 7-year-old children
of mothers randomised to receive FA in pregnancy
would remain evident in these children at 11 years, as
measured by both cognitive testing and MEG
assessment.
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Methods
Study population
This study was conducted as a follow-up investigation of
children at 11 years whose mothers participated in the
FASSTT trial in pregnancy, as described in detail
elsewhere [10]. Briefly, healthy pregnant women, aged
18–35 years with a singleton pregnancy and who had
taken 400 μg/day of FA in the first trimester (as per
current guidelines in the UK), were recruited from
antenatal clinics in Northern Ireland before the 14th
gestational week (GW). Women were excluded from
participation in the trial if they had a previous NTD-
affected pregnancy or were taking medications known to
interfere with folate or related B-vitamin metabolism.
Among the inclusion criteria were taking FA supple-
ments sometime in the 1st trimester at the recom-
mended use of 400 μg/day; this automatically excluded
any mother taking no FA or taking higher dose FA. At
the start of the second trimester, pregnant women were
stratified into tertiles of plasma homocysteine (a func-
tional marker of folate status) and subjects in each
stratum were randomised to receive FA (400 μg/day) or
placebo until the end of pregnancy (i.e. a total interven-
tion 26 weeks). FA supplements were distributed (in 7-
day pillboxes) to participants every 4 weeks and an
overall participant compliance rate of 93% was estimated
from records of unused tablets.
The current FASSTT Offspring study was conducted
from December 2017 to November 2018, when the child
was 11 years old (Fig. 1). Mother-child pairs were re-
cruited by invitation letter to attend an appointment at
the Nutrition Innovation Centre for Food and Health
(NICHE), Ulster University. All efforts were made to re-
cruit the maximum number of participants from the ori-
ginal FASSTT trial. If current contact details were not
readily available from our research records, the details
were traced through health records. Those who failed to
attend for appointment were offered an alternative date,
up to a maximum of five appointments. A participant in-
formation sheet was provided to the mother, whilst a
child-friendly version was provided to explain the study
to the child. In compliance with ethical requirements,
signed informed consent from the mother and assent
from the child were obtained at the beginning of the ap-
pointment. Ethical approval was granted by the Office
for Research Ethics Committees Northern Ireland
(ORECNI Ref: 12/NI/0077) and the study was registered
(www.isrctn.com/ISRCTN19917787).
Scale for intellectual development evaluation
Cognitive performance of the child was assessed by the
Wechsler Intelligence Scale for Children 4th UK Edition
(WISC-IV) using Q-interactive™ software (Pearson Edu-
cation Ltd., UK) and performed using iPads [13]. The
WISC-IV assessment is suitable for children from 6
years to 16 years and 11 months and provides com-
posite scores for specified cognitive IQ domains—Ver-
bal Comprehension, Perceptual Reasoning, Working
Memory and Processing Speed comprising 15 sub-
tests—which are combined to give one composite
score that represents the child’s general intellectual
ability (Full Scale IQ). The assessment of each child
lasted 90–120 min and the entire test battery was
completed in one session. To ensure an ideal environ-
ment for assessment of the child, the room was
bright, ventilated and free from distraction and inter-
ruptions. The same trained researcher (AC) con-
ducted the assessments of all children and was
blinded to the treatment allocation of the mother
during the FASSTT trial.
Magnetoencephalography acquisition and analysis
In a sub-sample of participants, MEG brain imaging was
performed in the Northern Ireland Functional Brain
Mapping (NIFBM) facility at the Intelligent Systems Re-
search Centre, Ulster University. Before beginning the
MEG task, participants were given verbal instructions
and watched a child-friendly video to explain MEG, as
produced by Aston University [14]. Once in the MEG
machine, the children were encouraged to remain as still
as possible and were provided with earphones, asked to
listen carefully and to try to understand the sentences.
Eye movements and heartbeat rhythm were monitored
by bipolar electrodes. Head movement was recorded
using head-position indicator (HPI) equipment with
coils placed on the scalp. For each participant, head
shape and HPI coil position were defined using a 3D
digitiser (Fastrak, USA). As no MRI scans were per-
formed for individual brain structures, in order to pro-
vide anatomically informed MEG analysis, the HPI
digitisation points were realigned to the individual head
shape for each participant and then registered to the re-
corded MEG data.
Based on our previous findings showing higher
word reasoning scores (verbal IQ) at 7 years in the
children of FASSTT trial participants randomised to
receive FA in pregnancy [11], and observational evi-
dence linking maternal folate deficiency in pregnancy
with lower language abilities in the child [9], a lan-
guage task was selected to test the underlying neuro-
physiological basis of language processing in this
study using MEG. For this purpose, we adapted a
high-level semantic language task [15] to compare the
difference in neural responses to two types of sen-
tences, which are rendered either congruent or incon-
gruent at the presentation of the final word (e.g. ‘The
baby was thirsty and wanted a drink of milk/fire’,
where ‘fire’ or ‘milk’ renders the sentence semantically
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incongruent, or congruent, respectively): (Add-
itional File 1: Methods). The MEG responses were re-
corded with the Elekta Neuromag 306-channel MEG
system (using the operating conditions as detailed in
Additional File 1: Methods). The band power in re-
sponse to the language paradigm was obtained from
116 brain regions and averaged within six standard
spectral bands: Big band [1–48 Hz], Theta [4–8 Hz],
Mu [8–12 Hz], Beta [13–30 Hz], Low Gamma [30–48
Hz] and High Gamma [49–70 Hz].
Data collection: related covariates
General health and lifestyle measures
Health and lifestyle information was gathered from the
mother using a detailed questionnaire that included in-
formation on socioeconomic status which was mapped
using house number, street name, postcode, town, and
the Land and Property Services Ordnance Survey of
Northern Ireland POINTER Geo-referencing database
[16]. After verifying the address information, all partici-
pants were geo-referenced and linked to an ‘area
Fig. 1 Diagrammatic protocol of the FASSTT Offspring trial at 11 years
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deprivation’ score based on the Census Output Area in
which they lived and using data from the Northern
Ireland Multiple Deprivation Measure 2010 (MDM)
score [17].
Standardised calibrated equipment was used to meas-
ure height (portable stadiometer, SECA, Birmingham),
head and waist circumference (non-stretchable tape) and
weight and body fatness (TANITA, TBF-410,
Netherlands). BMI Z-scores were calculated using World
Health Organization AnthroPlus software for assessing
growth in children and adolescents of 5–19 years [18].
Blood sampling and B-vitamin biomarkers
As previously detailed, non-fasting blood samples were
collected from the mother at 14th and 36th GW, and
the umbilical cord blood was collected at delivery [10].
For the current study, a paediatric phlebotomist ob-
tained non-fasting blood samples from the child at 11
years. All blood processing was carried out within 4 h of
collection and stored at − 80 °C until analysis. Samples
were analysed for serum and RBC folate, serum vitamin
B12 and plasma homocysteine using standard methods,
and riboflavin status was determined using the erythro-
cyte glutathione reductase activation coefficient (EGRac)
assay, as described elsewhere [19]. For each assay, quality
controls were provided by the repeated analysis of
pooled samples covering a wide range of values. Intraas-
say and interassay CVs were ≤ 8.2% for RBC folate, ≤
10.4% for serum vitamin B12, ≤ 2.5% for plasma
homocysteine and ≤ 2.8% for EGRac. Genotype for the
common C677T polymorphism in the gene encoding
methylenetetrahydrofolate reductase (MTHFR) was
identified using polymerase chain reaction amplification,
followed by HinF1 digestion.
Dietary analysis
Dietary intakes were evaluated using a 4-day food diary
(which included 2 weekdays and 2 weekend days) in
combination with a food frequency questionnaire (FFQ),
a method previously validated for folate and related B-
vitamin intakes against biomarker values, as described in
detail elsewhere [20]. Vitamin supplement use was also
recorded. Nutrient intakes were analysed using the
Nutritics nutritional software package [21], which was
customised to include the most recent nutritional con-
tent of fortified food products.
Statistical analysis
Confirmation that the sample size remained appropriate
for cognitive performance testing was based on the as-
sessment scores in the WPPSI-III test from these
children previously sampled at 7 years [11]. A sample
size of 37 children in each group was estimated to detect
a significant difference in cognitive performance between
the children of mothers randomised to FA versus pla-
cebo during pregnancy, with a power of 80% at α = 0.05.
Statistical analysis was performed using the Statistical
Package for the Social Sciences software (version 25.0;
SPSS UK Ltd., Chertsey, UK). Data not normally distrib-
uted were log-transformed before analysis. Differences
between placebo and treatment groups were analysed
using independent t tests for linear variables and χ2 tests
for categorical parameters. Raw cognitive scores were
automatically standardised for the child’s age at time of
testing, and appropriate age-specific reference intervals
were applied in adherence with test protocols. Analysis
of covariance (ANCOVA) was used to test for differ-
ences in cognitive test variables and MEG power (se-
mantic processing efficiency) between treatment groups,
with adjustment for relevant confounding factors, in-
cluding socioeconomic status (MDM score) [22] and




Of the 119 participants in the FASSTT trial [10], 68
mother-child pairs completed the FASSTT Offspring
trial at 11 years, representing a 57% response rate.
Maternal characteristics, including biomarker re-
sponses to intervention with FA or placebo during
pregnancy, were similar for mothers participating in
the current study as compared with the total sample
in the original trial (Additional File 1: Table S1). No
adverse events were reported at any time during the
original FASSTT trial or the follow-up studies of
mother-child pairs.
Maternal, neonatal and child health characteristics
are reported in Table 1, showing no significant differ-
ences in general characteristics between the FA and
placebo groups. In mothers during pregnancy, there
were also no significant differences between the treat-
ment groups in serum or RBC folate at the 14th GW
(pre-intervention), but after FA intervention for 26
weeks, these folate biomarkers were significantly higher
in the FA group in maternal (at 36 GW) and in cord
blood samples (Table 2). In children at 11 years, there
were no significant differences between the treatment
groups in dietary intakes or biomarkers of folate or
metabolically related B-vitamins. Mean dietary folate
and B-vitamin intakes compared favourably with Euro-
pean Food Safety Authority (EFSA) population refer-
ence intake (PRI) values for children 11–14 years [24],
and B-vitamin biomarker concentrations were in good
agreement with those reported in population-based sur-
veys in children from Norway [25], the UK [26] and the
USA [27].
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Effects of maternal FA intervention on child cognitive
performance
Full Scale IQ, composite domains and subtest scores
from FASSTT Offspring trial participants at 11 years are
presented in Table 3 and Additional File 1: Table S2.
The children of mothers randomised to FA compared
with placebo during pregnancy scored significantly
higher in two Processing Speed tests, i.e. symbol search
(+ 2.9 points) and cancellation (+ 11.3 points), whereas
the positive effect of prenatal FA on Verbal
Comprehension was significant in girls only (+ 6.5
points) (Table 3). At all FASSTT Offspring Trial time-
points, as currently assessed at 11 years and previously at
3 and 7 years, greater proportions of children from FA-
treated mothers compared with placebo had cognitive
scores above the median value of 10.0 (in the BSITD-III
test at 3 years), 23.0 (in the WPPSI-III test at 7 years)
and 102.5 (in the WISC-IV test at 11 years), albeit by 11
years, the effect of prenatal FA appeared to have dimin-
ished somewhat (Fig. 2). Of note, 71.4% of the children
Table 1 General characteristics of mother-child pairs from the FASSTT Offspring trial
Placebo (n = 31) Folic acid (n = 37)
Maternal characteristics at 14th GW
Age, years 28.1 (26.6, 29.6) 29.7 (28.5, 30.8)
BMI, kg/m2 25.2 (23.7, 26.7) 25.5 (23.6, 27.3)
Smoker, No. (%) 2 (6) 5 (14)
Duration of FA use at sampling, weeksa 13.3 (10.5, 16.0) 12.7 (10.3, 15.0)
Iron supplement use, No. (%) 6 (19) 11 (30)
Parity, No. 0.7 (0.4, 1.0) 0.9 (0.6, 1.2)
Caesarean section, No. (%) 9 (29) 10 (27)
Education, years 19.2 (18.3, 20.2) 19.6 (18.8, 20.4)
Married, No. (%) 24 (80) 33 (92)
Owner of dwelling, No. (%) 24 (80) 30 (83)
Rural dweller, No. (%) 16 (52) 22 (59)
Socioeconomic status (MDM score)b 21.9 (17.0, 26.8) 18.7 (15.3, 22.0)
Neonatal characteristics
Gestational age, weeks 40.2 (39.6, 40.7) 39.8 (39.4, 40.2)
Sex, male, No. (%) 15 (48) 16 (43)
Birth weight, g 3503 (3329, 3677) 3461 (3290, 3633)
Birth length, cm 51.1 (50.2, 52.0) 50.9 (50.1, 51.7)
Head circumference, cm 34.5 (34.0, 35.0) 34.6 (34.1, 35.1)
Apgar score at 1 min 8.4 (7.9, 8.8) 8.4 (8.0, 8.8)
Apgar score at 5 min 8.9 (8.8, 9.1) 8.9 (8.7, 9.1)
Breastfed, No. (%) 15 (48) 16 (43)
Child characteristics (11 years)
Age, years 10.8 (10.7, 10.8) 10.8 (10.7, 11.0)
Siblings, No. 1.9 (1.5, 2.3) 1.7 (1.5, 2.0)
Weight, kg 39.3 (35.8, 42.8) 37.7 (35.3, 40.1)
Height, cm 147.1 (144.8, 149.3) 146.7 (144.0, 149.3)
BMI for age Z-scorec 0.15 (− 0.33, 0.62) − 0.03 (− 0.45, 0.38)
Waist circumference, cm 71.1 (67.3, 74.9) 68.2 (65.6, 70.7)
Head circumference, cm 55.2 (54.2, 56.2) 54.7 (54.0, 55.4)
Body fatness, % 19.6 (15.8, 23.3) 19.2 (16.5, 21.9)
Continuous measures presented as mean (95% CI), unless otherwise indicated; compared by independent t-test. Categorical measures compared using
Pearson’s chi-square
aThe duration of FA use refers to the total number of weeks, from initiating FA supplements to time of sampling at the 14th gestational week of pregnancy
bNorthern Ireland Multiple Deprivation Measure 2010 (MDM). This is a measure of socioeconomic area-based deprivation and comprises 7 domains, each
developed to measure a distinct form of deprivation: income, employment, health, education, proximity to services, living environment and crime
cZ-scores for BMI were calculated using the WHO AnthroPlus software [18]
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from FA-treated mothers who had cognitive scores above
the median at 11 years also scored above the median at 7
years and the Full Scale IQ scores at these time points
were significantly correlated (r = 0.463; p < 0.0001).
Effects of maternal FA intervention on child brain
function response
MEG brain imaging was offered to all the participants in
the trial, but owing to practical considerations (including
Table 2 Folate and related B-vitamin status of mother-child pairs from the FASSTT Offspring trial
Placebo (n = 31) Folic acid (n = 37) p value
Mothers during pregnancy
Preintervention (14th gestational week)
Dietary intakes
Energy, MJ/day 8.463 (7.631, 9.296) 7.995 (7.468, 8.522) 0.31
Dietary folate equivalents, μg/day 371 (306, 437) 388 (329, 447) 0.71
B vitamin status
Serum folate, nmol/L 50.5 (43.1, 57.9) 49.9 (42.8, 57.1) 0.91
RBC folate, nmol/L 1055 (839, 1271) 1271 (1059, 1482) 0.15
Serum B12, pmol/L 236 (209, 264) 233 (206, 259) 0.85
Plasma homocysteine, μmol/L 6.1 (5.6, 6.6) 6.1 (5.6, 6.6) 0.96
MTHFR 677TT genotype, No. (%) 4 (13) 5 (14) 0.91
Postintervention (36th GW)
Serum folate, nmol/L 22.4 (15.9, 28.8) 52.9 (45.8, 60.0) < 0.001
RBC folate, nmol/L 907 (722, 1042) 1864 (1650, 2078) < 0.001
Serum B12, pmol/L 169 (151, 188) 175 (152, 198) 0.98
Plasma homocysteine, μmol/L 7.2 (6.5, 7.9) 6.3 (5.8, 6.8) 0.04
Neonates at birth
Serum folate, nmol/L 68.2 (57.8, 78.5) 105.2 (93.4, 117.0) < 0.001
RBC folate, nmol/L 1512 (1272, 1752) 2216 (1856, 2575) 0.001
Serum B12, pmol/L 286 (230, 342) 259 (216, 302) 0.42
Plasma homocysteine, μmol/L 9.6 (7.7, 11.4) 10.4 (8.9, 11.9) 0.35
MTHFR 677TT genotype, No. (%) 3 (13) 4 (13) 0.99
Children at 11 years
Vitamin supplement user, No. (%) 9 (30) 8 (22) 0.62
Fortified food consumer, No. (%) 28 (93) 33 (89) 0.87
Dietary intakesa PRIc
Energy, MJ/day 6.400 6.676 (6.118, 7.234) 6.746 (6.088, 7.404) 0.87
Dietary folate equivalents, μg/day 270 276 (234, 317) 265 (232, 299) 0.66
Vitamin B12, μg/day 3.5 4.4 (3.6, 5.2) 4.1 (3.5, 4.6) 0.55
Riboflavin, mg/day 1.4 1.7 (1.4, 2.0) 1.6 (1.4, 1.8) 0.49
Vitamin B6, mg/day 1.4 1.6 (1.5, 1.8) 1.6 (1.4, 1.8) 0.73
Biomarker statusb cut-offc
RBC folate, nmol/L > 309 595 (502, 688) 662 (513, 810) 0.45
Serum B12, pmol/L > 172 511 (418, 605) 529 (460, 598) 0.75
Riboflavin, EGRacd < 1.40 1.48 (1.38, 1.58) 1.44 (1.37, 1.52) 0.54
Plasma homocysteine, μmol/L < 10.7 6.9 (6.1, 7.7) 6.9 (5.8, 8.0) 0.94
Data presented as mean (95% CI), unless otherwise indicated. Differences between groups were assessed using an independent t test (continuous variables) or
chi-square test (categorical variables). Statistically significant difference p < .05
aChildren who provided dietary intake data n = 48 (placebo n = 21; FA n = 27)
bChildren who provided a blood sample n = 33 (placebo n = 16; FA n = 17)
cPopulation reference intakes from EFSA (2017) [24] and biomarker reference ranges from Kerr et al. (2009) [26]
dEGRac, erythrocyte glutathione reductase activation coefficient (biomarker of riboflavin status; a higher EGRac ratio indicates lower riboflavin status). Suboptimal
riboflavin status is indicated by an EGRac value of 1.30–1.40 whereas ≥ 1.40 is considered deficient
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the requirement to undertake a 2-h return journey to our
NIFBM centre), not all children participated in this com-
ponent. Of the 68 mother-child pairs in the current
follow-up study, 33 children also completed the MEG as-
sessment. Maternal characteristics measured during preg-
nancy in this sub-sample were similar to those of the total
sample of FASSTT trial participants (Additional File 1:
Table S3). MEG assessment of neuronal responses to a
language task showed increased power at the Beta (13–30
Hz) and High Gamma (49–70Hz) bands in children from
FA-supplemented mothers compared to placebo, indicat-
ing predominant involvement of local neurons, and in
turn, more efficient semantic processing of language
(Table 3). Given that the MEG brain imagining was con-
ducted only in a subset of children (i.e. 49% of child par-
ticipants), the MEG results were not analysed by sex.
In addition, power at the Beta band in children was sig-
nificantly correlated with maternal serum and RBC folate
concentrations at the 36th GW of pregnancy (r = 0.439,
p = 0.02; n = 33 and r = 0.393, p = 0.03; n = 32, respect-
ively). Furthermore, when maternal serum folate at the
36th GW was dichotomised into lower and higher status
categories based on the median value, higher maternal fol-
ate was associated with significantly higher power at the
Beta (mean difference 90.7 points, 95% CI 22.5 to 158.9,
p = 0.002), but not High Gamma (14.8, − 85.9 to 56.3, p =
0.99), band in the child at 11 years, after adjustment for
the child’s sex and socioeconomic status. Similar correla-
tions for cord blood folate status with MEG were found,
specifically, serum folate was significantly associated with
power at the Beta band (r = 0.439, p = 0.03; n = 26). Like-
wise, in children with higher cord blood folate, we found
Table 3 WISC-IV cognitive assessment and MEG brain imaging in FASSTT Offspring trial participants
Placebo (n = 31) Folic acid (n = 37) Difference p valuea p valueb
WISC-IV assessment
Full Scale IQ 101.5 (96.9, 106.0) 102.8 (99.5, 106.1) 1.3 (− 4.1, 6.7) 0.63 0.85
Boys 103.2 (95.7, 110.7) 101.3 (95.6, 107.0) 1.9 (− 10.9, 7.1) 0.66 0.61
Girls 99.9 (93.8, 106.1) 103.8 (99.5, 108.1) 3.8 (− 3.2, 10.8) 0.28 0.44
Verbal Comprehension 95.0 (90.9, 99.1) 97.5 (94.6, 100.3) 2.5 (− 2.4, 7.3) 0.31 0.45
Boys 97.9 (89.9, 105.9) 95.2 (90.5, 99.9) 2.7 (− 11.6, 6.1) 0.53 0.48
Girls 92.4 (88.5, 96.3) 99.0 (95.2, 102.7) 6.5 (1.2, 11.8) 0.02 0.03
Perceptual Reasoning 106.3 (101.4, 111.2) 104.5 (100.9, 108.2) 1.8 (− 7.6, 4.0) 0.54 0.45
Boys 107.3 (100.3, 114.3) 104.1 (97.5, 110.6) 3.2 (− 12.3, 5.9) 0.47 0.51
Girls 105.5 (98.0, 113.0) 104.9 (100.2, 109.5) 0.6 (− 8.7, 7.5) 0.87 0.85
Working Memory 96.9 (92.3, 101.5) 98.4 (85.5, 101.3) 1.5 (− 3.6, 6.6) 0.55 0.76
Boys 98.2 (92.1, 104.3) 98.4 (93.1, 103.7) 0.2 (− 7.5, 7.8) 0.96 0.97
Girls 95.8 (88.6, 103.1) 98.4 (94.8, 102.0) 2.6 (− 4.6, 9.8) 0.47 0.74
Processing Speed 104.2 (98.9, 109.6) 109.2 (105.9, 112.5) 4.9 (− 1.0, 10.9) 0.10 0.16
Boys 102.3 (94.0, 110.5) 108.4 (102.6, 114.3) 6.1 (− 3.5, 15.8) 0.20 0.21
Girls 105.9 (98.2, 113.7) 109.7 (105.4, 113.9) 3.7 (− 4.3, 11.7) 0.35 0.64
Coding subtest 47.9 (44.5, 51.3) 49.0 (46.6, 51.4) 1.1 (− 2.7, 5.0) 0.78 0.73
Symbol search subtest 24.6 (22.3, 26.9) 27.5 (26.2, 28.8) 2.9 (0.3, 5.5) 0.03 0.03
Cancellation subtest 83.7 (75.8, 91.6) 95.0 (89.6, 100.3) 11.3 (2.5, 20.1) 0.05 0.04
MEG band power in response to the language paradigmc
Broad [1–48 Hz]d 48.9 (14.6, 83.2) 32.9 (6.7, 59.0) 16.1 (− 56.6, 24.5) 0.43 0.41
Theta [4–8 Hz] 90.8 (38.1, 143.4) 65.3 (28.7, 102.0) 25.5 (− 84.9, 34.0) 0.36 0.21
Mu [8–12 Hz] 53.9 (26.1, 81.6) 39.2 (15.1, 63.3) 14.6 (− 49.8, 20.5) 0.39 0.46
Beta [13–30 Hz] 26.4 (2.7, 50.1) 109.6 (52.4, 166.8) 83.2 (15.0, 151.4) 0.02 0.01
Low Gamma [30–48 Hz] 40.5 (− 7.6, 88.5) 45.3 (16.0, 74.5) 4.8 (− 46.5, 56.1) 0.49 0.39
High Gamma [49–70 Hz] 30.1 (− 4.4, 64.6) 100.8 (48.6, 153.0) 70.7 (6.5, 135.0) 0.04 0.04
Data presented as mean (95% CI), unless otherwise indicated. Differences between groups were analysed by aindependent t test or bANCOVA adjusting for
covariates: Multiple Deprivation Measure and child’s sex. Statistically significant difference p < .05
cMEG analysis completed in a subset of children: placebo, n = 14; folic acid, n = 19. Differences between groups were analysed by aindependent t test or bANCOVA
adjusting for child’s sex
dBroad band [1–48 Hz] is comprised of Theta, Mu, Beta and Low Gamma bands
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significantly higher power at the Beta band (65.0, 95% CI
− 10.4 to 140.4, p = 0.05) at 11 years.
Discussion
We examined the effect of FA intervention in trimesters
2 and 3 of pregnancy in women taking FA as recom-
mended in the first trimester, and provide the first
randomised trial evidence that continued FA supplemen-
tation (400 μg/day) throughout pregnancy can influence
cognitive performance and brain function of the child
up to 11 years of age. The results not only provide a fur-
ther follow-up from the FASSTT Offspring study to
reinforce our previous findings of cognitive benefits in
these children at 3 and 7 years but provide the first
MEG brain imaging evidence that FA supplementation
in pregnancy can impact brain function in the child.
Our results, reporting the third follow-up of mother-
child pairs from the FASSTT trial, show that the 11-
year-old children of mothers randomised to FA com-
pared with placebo during trimesters 2 and 3 of preg-
nancy scored significantly higher in specified cognitive
IQ domains of the WISC-IV assessment, namely, two
Processing Speed tests, i.e. symbol search (by 2.9 points)
and cancellation (by 11.3 points), and Verbal Compre-
hension (by 6.5 points) in girls. The results are entirely
consistent with our earlier findings in these children at a
younger age, showing higher scores in overall cognition
at 3 years and in verbal IQ at 7 years in the offspring of
FA-treated mothers in pregnancy [11]. Here we show
that at all time-points up to age 11 years, greater propor-
tions of children from FA-treated mothers, compared
with placebo, had cognitive scores above the median
values of 10.0 in the BSITD-III test (at 3 years), 23.0 in
the WPPSI-III test (at 7 years) and 102.5 in the WISC-
IV test (at 11 years). The FASSTT Offspring trial thus
provides more robust evidence of the role of maternal
folate status in offspring cognitive function compared
with previous observational studies that have reported
positive associations between FA use in early pregnancy
(as retrospectively reported by mothers) or maternal fol-
ate concentrations, and cognitive performance in the
child [6, 28, 29]. The role of maternal folate beyond the
first trimester of pregnancy has been far less frequently
investigated in previous studies, but one notable study
found that higher plasma folate at the 30th gestational
week was associated with better cognitive performance
in over 500 children aged 9–10 years in South India [8].
Our results are thus consistent with previous observa-
tions, but add considerably to the evidence, and indicate
that FA intervention throughout pregnancy will have
beneficial effects on cognitive performance in the child
up to 11 years. Of note, folate intake and status of the
Fig. 2 Percentage of FASSTT Offspring participants at 3, 7 and 11 years achieving above average cognitive performance by treatment allocation
of the mother during pregnancy. In children at 3 years, cognitive performance was assessed by the BSITD-III test, at 7 years by the WPPSI-III test
and at 11 years by the WISC-IV test. Values are percentage of children at 3, 7 or 11 years, by treatment group of the mother, who achieved above
the median cognitive score for children at that age (relative to those who scored at and below the median score); median scores are 10.0 in the
BSITD-III test, 23.0 in the WPPSI-III test and 102.5 in the WISC-IV test. Total participants numbers at each age are 3 years, n = 39; 7 years, n = 70; and
11 years, n = 68. 71.4% of the children from FA-treated mothers who had cognitive scores above the median at 11 years also scored above the
median at 7 years and Full Scale IQ scores at these time points were significantly correlated (r = 0.463; p < 0.0001)
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children were considered in this study and found to be
similar in both study groups, with dietary folate compar-
ing favourably with reference values for this age group
[24] and biomarker concentrations in good agreement
with those reported in children from Norway [25], UK
[26] and USA [27].
The current sex-specific findings, showing a positive
effect of prenatal FA on verbal IQ in 11-year-old girls
(by 6.5 points), but not in boys, are not entirely unex-
pected given existing evidence of sex differences in brain
activity patterns associated with cognition and behaviour
and in functional brain development in infancy and early
childhood [4]. Also, between 3 and 60 months, females
are reported to exhibit a higher rate of myelination than
do males in the genu of the corpus callosum, in left
frontal and left temporal white matter and in the right
optic radiation [30]. Furthermore, in previous epigenetic
analysis of cord samples from these children at birth, we
investigated candidate genes related to brain develop-
ment or function and reported significant DNA methyla-
tion effects in IGF2 in girls, but not in boys, arising from
maternal FA intervention [31], perhaps offering a bio-
logical basis for the sex-differences found here in the re-
lationship of prenatal FA with cognitive outcomes in
childhood. Sex differences in brain development, how-
ever, likely reflect a dynamic interplay of many biological
(e.g. prenatal and neonatal hormone production and dir-
ect sex chromosome effects) and other mechanisms [4].
In any case, this aspect requires further investigation.
In addition to using standardised IQ tests to measure
child cognition, we applied magnetoencephalographic
brain imaging for the first time in a study of this kind.
In broad support of the cognitive outcomes, the
neuronal activity assessments using MEG indicated more
efficient semantic processing of language in the 11-year-
old child as a result of prenatal intervention with FA.
Specifically, the increased power at Beta and High
Gamma bands in response to the language task in chil-
dren from the FA group suggest more active engage-
ment of local neuronal networks. Previously, increased
power at the High Gamma band using MEG was re-
ported as a result of intensive computer-based training
[32]. The fact that we observed similar band power pat-
terns in response to the language task in children of FA-
supplemented mothers to those reported in children
with enhanced cognition as a consequence of intensive
training suggests that the current MEG findings are clin-
ically relevant.
The finding of FA-related effects in language process-
ing as assessed by MEG is broadly in line with the higher
verbal comprehension scores in the current WISC-IV as-
sessment at 11 years and our earlier findings of higher
verbal IQ in these children at 7 years in response to pre-
natal FA. Likewise, a recent study reported greater
cerebral cortical thickness in children aged 8–18 years
who were exposed prenatally to population-wide FA for-
tification compared to those born before the introduc-
tion of this mandatory policy in the USA [33], whilst in
the Generation R Study, maternal folate deficiency
diagnosed after the first trimester was associated with re-
duced brain volume (measured using magnetic reson-
ance imaging) in 6–8 year old Dutch children [9]. Thus,
our randomised trial results, together with the available
observational evidence, are consistent in indicating that
prenatal maternal FA supplementation affects neurocog-
nitive development and may have a specific role in se-
mantic processing of language up to 11 years. In
addition, there may be clinical implications of our find-
ings for later life in that the achievement of full cognitive
potential of the child is considered paramount for future
academic attainment, and higher intelligence in child-
hood is associated with better cognitive reserves in
adulthood that could potentially delay cognitive decline
in later life [34, 35]. Future MEG studies might investi-
gate the functional neural connectivity patterns within
emerging neural networks, both in resting-state and
under task conditions, that support developing language
and cognition.
Although the precise mechanism explaining the effect
of FA during pregnancy on neurodevelopment of the
child is unknown, it must in some way involve the es-
sential role of folate in one-carbon metabolism, encom-
passing a complex network of interdependent pathways
required for a number of biological processes that could
impact neurodevelopment, including myelination,
neurotransmitter synthesis and methylation [36]. It is
also possible that folate-related epigenetic changes via
DNA methylation are involved [3]. In previous epigen-
etic analysis of cord blood samples in these children as
newborns, using a candidate gene approach we showed
that prenatal FA throughout pregnancy resulted in sig-
nificant effects in DNA methylation in specific genes
linked with brain development or function (IGF2, BDNF
and the widely dispersed retrotransposon, LINE-1) [31],
and in epigenome-wide screening of the same samples,
we identified a novel mechanism for folate-dependent
regulation of the ZFP57 gene [37].
The main strength of this study is the research design,
involving a follow-up study in children of mothers who
had participated in a randomised trial in pregnancy,
which enabled the demonstration of a causative link be-
tween prenatal FA and subsequent neurocognitive devel-
opment in the child. The use in a sub-set of children of
the neuroimaging technique, MEG, objectively investi-
gated the effects of FA intervention in pregnancy on
brain function in childhood. Furthermore, this is the
third follow-up of the FASSTT Offspring cohort (with
previous investigations at age 3 and 7 years), providing
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the opportunity to track cognitive development in child-
hood, and the broad agreement in results at all time-
points provides some degree of internal validation to the
findings. In addition, a range of factors previously re-
ported to be associated with cognitive performance, and
thus potential confounders in the relationship between
prenatal FA and offspring intelligence, were considered
[23, 38]. However, this study also has limitations, the
most notable of which is the relatively small sample size.
Although every effort was made to maximise the partici-
pation rate from the original FASSTT trial (n = 119), the
final sample of 68 mother-child pairs may have lacked
sufficient statistical power to detect small differences in
some components of the WISC-IV cognitive test. Also
paternal factors, recently emerging as potentially import-
ant for child neurocognitive development, were not
considered.
Conclusions
In summary, our findings in the children of participants
in a randomised trial in pregnancy add considerably to
the existing evidence from observational studies that
have linked maternal folate status in pregnancy with
neurocognitive outcomes in the child. We examined the
effect of FA intervention in trimesters 2 and 3 of preg-
nancy (in women taking FA as recommended in the first
trimester), and provide the first randomised trial evi-
dence that continued FA supplementation (400 μg/day)
throughout pregnancy can influence cognitive perform-
ance and brain function of the child up to 11 years of
age. In addition to using standardised IQ tests to meas-
ure child cognition, we applied magnetoencephalo-
graphic brain imaging for the first time in a study of this
kind, and the findings not only reinforce our previous
findings of cognitive benefits in these children at 3 and
7 years but provide new evidence of a specific role of
prenatal FA in semantic processing of language. The to-
tality of evidence has important impacts in informing
new policy and clinical practice in relation to FA use in
pregnancy. Whereas current recommendations for NTD
prevention in the UK and most countries worldwide ad-
vise mothers to take FA supplements from before con-
ceiving until the end of the 12th gestational week only,
our findings suggest that continued FA intervention in
pregnancy beyond the early period required to prevent
NTD is beneficial to neurocognitive development in the
child. In a wider context, we demonstrate the application
of MEG as a non-invasive tool in paediatric research to
objectively assess functional brain activity in response to
nutrition and other interventions.
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